Research Studies
Back to Results
Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3B) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies
Details
Age
Child to Adult
Phase
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Type of Study
Treatment
Location
Childrens Hospital Colorado
Principal Investigator
Margaret Macy
Study ID
Protocol Number: 20-1445
More information available at ClinicalTrials.gov: NCT04239092
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers